Cytori Therapeutics Inc. 2011年06月02日 11時55分
From JCN Newswire

San Diego, CA, June 2, 2011 - ( JCN Newswire ) - Cytori Therapeutics (NASDAQ: CYTX) は、Cytoriの Celution(R) Systemのような閉鎖系システムを使用して、脂肪組織由来幹細胞を含む再生細胞(ADRC)を多く含むよう処理した脂肪グラフトの作製に関する特許第4722041号(041号特許)を、日本特許庁から取得しました。この特許は、同社の再生細胞を多く含むよう処理した脂肪移植の適用を、日本において明確に保護しています。適用の対象となるのは、乳房再建および他の軟部組織欠損治療、尿失禁治療および美容を目的とした処置等です。



About Cytori

Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource(R) product line is sold globally for cell banking and research applications. Our PureGraft(TM) products are available in North America and Europe for fat grafting procedures. www.cytori.com リンク

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, such as No. 4722041 patent's ability to protect our Products, which could affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2010. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.

Tom Baker

Megumi Okabe

概要:Cytori Therapeutics Inc.